One of the best-known examples in human genetics of a disease shaping the genome directly — and a 2013 study found even its most famous protective variant works differently in different African populations.
Malaria is a mosquito-borne infectious disease caused by Plasmodium parasites, historically one of the strongest known forces shaping human genetic variation. This page holds 2 variants from a large multi-population African genetic study.
A 2013 study analyzed genome-wide data from ~5,000 people with severe malaria and 7,000 population controls across three different locations in Africa. The study's first purpose was methodological: genome-wide association analysis tools were built and refined largely on European-ancestry populations, where genetic diversity is comparatively limited — the study tested whether the same standard approach could still reliably detect known malaria susceptibility loci in Africa, where genetic diversity within and between populations is far more extensive. It confirmed the standard approach works at sufficient sample sizes, and that modern methods can control for the confounding effects of population structure.
The study's most striking specific finding involves rs12788102, in HBB — the hemoglobin beta gene, home to the haemoglobin S allele (the sickle-cell trait variant), one of the longest-known and best-established protective factors against severe malaria. The pattern of genetic association around this allele differed substantially across the three African populations studied, due to differences in the surrounding haplotype structure — the same well-known protective gene does not behave as one uniform, transportable effect across all African populations. This finding motivated the paper's new statistical methods: relaxing standard fixed-effect assumptions, applying Bayesian approaches to allow for effect differences across studies, and introducing a region-based test that allows for uncertainty in exactly where within a region a causal variant sits. This page's second variant, rs8176722, is in ABO, the blood-group gene.
2026-07-01 · Nature 2026, PMID:42386975
Verified directly against the paper's own abstract via Europe PMC (PMID:42386975, Nature, July 2026). Researchers used immunopeptidomics to identify Plasmodium-derived peptide fragments displayed by HLA-I molecules on infected liver cells, finding 453 unique peptides from 166 proteins. 75 of these came from housekeeping proteins expressed across multiple parasite life stages and conserved between Plasmodium species -- not strain-specific targets that mutate away. These peptides were presented across HLA-A, HLA-B, HLA-C and the non-classical, nearly invariant HLA-E. Antigenicity was confirmed in both P. vivax and P. falciparum-infected people, and T cell responses were seen in non-human primates after infection or immunization, with two antigens showing protective CD8+ T cell immunity in rodent testing. The paper frames this as a blueprint for a T-cell-based vaccine effective against the parasite's huge existing diversity, since these targets are shared and don't drift the way surface-protein vaccine targets have. This is a host-immune-recognition/HLA finding, not directly about this page's own variants (ABO, HBB), but it involves the same HLA machinery broadly relevant to this site's infectious-disease genetics coverage.
Malaria is diagnosed by blood smear microscopy or rapid antigen testing for the Plasmodium parasite — not by genotype. None of the 2 variants on this page are used by any guideline to diagnose malaria or select treatment.
The loci described above come from one of the largest African-population malaria genetic studies to date. The HBB/haemoglobin S finding in particular reflects one of the best-established gene-disease relationships in human genetics — but even here, the specific pattern varies meaningfully by population, underscoring that this is population-level evidence about susceptibility, not an individual predictive or diagnostic test.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Malaria comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Malaria. MyGeneLog™. https://www.mygenelog.com/conditions/malaria
A mosquito-borne infectious disease caused by Plasmodium parasites, one of the leading causes of infectious disease death globally, concentrated in sub-Saharan Africa.
The haemoglobin S allele (the sickle-cell trait variant) in the HBB gene is one of the longest and best-established protective factors against severe malaria -- though a 2013 study found its specific genetic association pattern varies by African population.
Carrying one copy of the sickle-cell variant (haemoglobin S) is well established to reduce severe malaria risk; carrying two copies causes sickle cell disease. This page's variant sits in that same HBB gene.
No. Malaria is diagnosed by blood smear or rapid antigen testing. These are population-level genetic findings from African cohorts, not a way to predict an individual case.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.